MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Search

Harvard Bioscience Inc

Atvērts

SektorsVeselības aprūpe

0.6 3.45

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.56

Max

0.61

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1M

-1.2M

Pārdošana

141K

21M

Peļņas marža

-5.978

Darbinieki

330

EBITDA

1M

1.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+244.83% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 11. marts

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

616K

26M

Iepriekšējā atvēršanas cena

-2.85

Iepriekšējā slēgšanas cena

0.6

Ziņu noskaņojums

By Acuity

26%

74%

71 / 360 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Harvard Bioscience Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. janv. 23:49 UTC

Galvenie tirgus virzītāji

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026. g. 21. janv. 21:12 UTC

Galvenie tirgus virzītāji

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 21:00 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026. g. 21. janv. 20:29 UTC

Galvenie tirgus virzītāji

Chip Makers Gain After Trump Calls Off European Tariffs

2026. g. 21. janv. 20:04 UTC

Galvenie tirgus virzītāji

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026. g. 21. janv. 23:34 UTC

Tirgus saruna

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026. g. 21. janv. 22:39 UTC

Peļņas

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 21. janv. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026. g. 21. janv. 21:19 UTC

Peļņas

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026. g. 21. janv. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026. g. 21. janv. 20:36 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026. g. 21. janv. 20:31 UTC

Tirgus saruna

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026. g. 21. janv. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Was It a 'TACO' Event? -- Market Talk

2026. g. 21. janv. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026. g. 21. janv. 20:23 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026. g. 21. janv. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026. g. 21. janv. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Group Agrees to Buy Allfunds

2026. g. 21. janv. 20:08 UTC

Peļņas

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026. g. 21. janv. 20:03 UTC

Tirgus saruna

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026. g. 21. janv. 19:51 UTC

Tirgus saruna

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026. g. 21. janv. 19:43 UTC

Tirgus saruna

U.S. Ethanol Production Expected to Slip -- Market Talk

2026. g. 21. janv. 19:31 UTC

Tirgus saruna

Gold Settles at Fresh All-Time High -- Market Talk

2026. g. 21. janv. 19:24 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026. g. 21. janv. 19:10 UTC

Tirgus saruna

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026. g. 21. janv. 18:57 UTC

Tirgus saruna

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Salīdzinājums

Cenas izmaiņa

Harvard Bioscience Inc Prognoze

Cenas mērķis

By TipRanks

244.83% augšup

Prognoze 12 mēnešiem

Vidējais 2 USD  244.83%

Augstākais 2 USD

Zemākais 2 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harvard Bioscience Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.3 / 0.3401Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

No Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

71 / 360 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat